Morgan Stanley Brooklyn Immuno Therapeutics, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.23 - $0.71 $6,057 - $18,700	-26,339 Reduced 66.01%	13,561 $3,000
Q2 2022 Oct 27, 2022	SELL	$0.48 - $2.03 $330,095 - $1.4 Million	-687,699 Reduced 94.52%	39,900 $21,000
Q2 2022 Aug 15, 2022	SELL	$0.48 - $2.03 $330,095 - $1.4 Million	-687,699 Reduced 94.52%	39,900 $21,000
Q1 2022 Oct 27, 2022	BUY	$1.76 - $4.84 $1.21 Million - $3.33 Million	687,699 Added 1723.56%	727,599 $1.49 Million
Q1 2022 May 13, 2022	BUY	$1.76 - $4.84 $321,583 - $884,355	182,718 Added 33.53%	727,599 $1.49 Million
Q4 2021 Feb 14, 2022	BUY	$4.17 - $9.79 $2.23 Million - $5.23 Million	534,556 Added 5177.3%	544,881 $2.27 Million
Q3 2021 Nov 15, 2021	BUY	$8.86 - $17.05 $91,479 - $176,041	10,325 New	10,325 $97,000

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.